However,both drugs can cause severe hemolysis in persons with glucose-6-phosphatedehydrogenase (G6PD) deficiency,6 whichaffects up to 30% of the population in regions where malaria is present.7 By exploring PlasmodiumN-myristoyltransferase (NMT) as a target, we hope to overcomeboth roadblocks. This evidence concerns the gene NMT1 and malaria.